DrugPatentWatch Database Preview
Patent: 10,189,903
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for Patent: 10,189,903
| Title: | Bispecific chimeric antigen receptors and methods of use thereof to treat cancer |
| Abstract: | The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors. |
| Inventor(s): | Jensen; Michael (Bainbridge, WA) |
| Assignee: | Seattle Children\'s Hospital (Seattle, WA) |
| Application Number: | 15/233,140 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,189,903
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | Seattle Children\'s Hospital (Seattle, WA) | 2032-02-13 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Seattle Children\'s Hospital (Seattle, WA) | 2032-02-13 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Seattle Children\'s Hospital (Seattle, WA) | 2032-02-13 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Seattle Children\'s Hospital (Seattle, WA) | 2032-02-13 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,189,903
| Country | Patent Number | Publication Date |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013123061 | Aug 22, 2013 |
| United States of America | 2015038684 | Feb 05, 2015 |
| United States of America | 2017107285 | Apr 20, 2017 |
| United States of America | 2019119382 | Apr 25, 2019 |
| >Country | >Patent Number | >Publication Date |
